Clinical trials: Episodic Migraine Headache
Migraine, Episodic Migraine
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
- Trial name
- CHALLENGE-MIG (NCT05127486)
- Testing
- Galcanezumab, Rimegepant
- Where
- 77 sites in United States
- Volunteers
- 580 people
- Sponsor
- Eli Lilly and Company
Migraine
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.
- Trial name
- EVOLVE-2 (NCT02614196)
- Testing
- Galcanezumab
- Where
- 113 sites in United States, Argentina and 10 more
- Volunteers
- 986 people
- Sponsor
- Eli Lilly and Company
Migraine Headaches
An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.
- Trial name
- NCT02856802
- Testing
- Sumatriptan 10 mg Nasal Spray
- Where
- 9 sites in United States
- Volunteers
- 107 people
- Sponsor
- Upsher-Smith Laboratories
Episodic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine.
- Trial name
- E-BEOND (NCT06047457)
- Testing
- Botulinum toxin type A
- Where
- 105 sites in United States, Canada and 6 more
- Volunteers
- 751 people
- Sponsor
- Ipsen
Migraine With or Without Aura
The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination
The Preventive Treatment of Migraine with Low-Dose Naltrexone and Acetaminophen Combination: A Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders
- Trial name
- NCT03194555
- Testing
- Low-Dose Naltrexone and Acetaminophen Combination
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine
Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
Migraine is a very common, neurological disorder, characterized by recurrent episodes of headache, potential progression to more frequent and severe attack patterns, and associated symptoms.
- Trial name
- COMIG (NCT04114630)
- Testing
- erenumab 70mg/mL
- Where
- 27 sites in Spain
- Sponsor
- Novartis Pharmaceuticals
Migraine
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
A migraine is a moderate to severe headache on one side of the head that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- ATO-TOPIRAMATE (NCT05748483)
- Testing
- Atogepant, Topiramate
- Where
- 81 sites in Austria, Belgium and 10 more
- Volunteers
- 545 people
- Sponsor
- AbbVie
Migraine, Episodic Migraine
Transnasal Cooling for Migraine
This is a prospective, double-blind, sham-controlled, randomized study to assess the safety, tolerability, and optimal dose of the COOLSTAT Transnasal Thermal Regulating Device for acute treatment of migraine.
- Conditions
- Migraine, Episodic Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT04936061
- Testing
- CoolStat active device
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- CoolTech LLC
Migraine, Headache
A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)
The purpose of this study is to evaluate the safety and efficacy of MK-6096 versus placebo for preventing migraines in participants with episodic migraine.
- Trial name
- NCT01513291
- Testing
- MK-6096
- Volunteers
- 237 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine Attacks
This study is a prospective, multi-centre, randomised, double-blind, sham-controlled investigation designed for comparison of two parallel treatment groups: gammaCore (active nVNS treatment) and a Sham device (control treatment)…
- Trial name
- NCT02686034
- Testing
- gammaCore-S
- Where
- 10 sites in Italy
- Volunteers
- 285 people
- Sponsor
- ElectroCore INC
Migraine
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
- Trial name
- NCT04825678
- Testing
- Erenumab
- Where
- 42 sites in United States
- Volunteers
- 240 people
- Sponsor
- Amgen
Migraine Disorders, Headache Disorders
Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the Smartphone
This study is conducted at the Henry Ford Health System with Lifegraph's behavioral monitoring technology, to examine the relation between migraine attacks and behavioral and environmental changes as detected from the smartphone…
- Conditions
- Migraine Disorders, Headache Disorders, Headache Disorders, Primary, Brain Diseases
- Trial name
- Migraine (NCT03762902)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Lifegraph Ltd.
Migraine Disorders, Refractory Migraine
EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization
This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal…
- Conditions
- Migraine Disorders, Refractory Migraine, Chronic Migraine
- Trial name
- EMBRACE (NCT07313800)
- Testing
- TEMMA Endovascular Treatment
- Where
- United States
- Sponsor
- Cortex Neurovascular
Episodic Migraine, Chronic Migraine
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
- Trial name
- NCT04686136
- Testing
- Atogepant 60 mg
- Where
- 116 sites in United States, Canada and 12 more
- Volunteers
- 596 people
- Sponsor
- AbbVie
Migraine
MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)
A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.
- Trial name
- NCT00797667
- Testing
- Telcagepant 140 mg, Telcagepant 280 mg
- Volunteers
- 660 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- PRACTICE (NCT07690215)
- Volunteers
- 200 people
- Sponsor
- AbbVie
Migraine
Fremanezumab Managed Access Program for Pediatric Patients
This is a Managed Access Program (MAP) based on a licensed physician's unsolicited request on a compassionate basis. Specifically, this MAP is for male and female pediatric patients 6 to 17 years with a diagnosis of either…
- Trial name
- NCT03539393
- Testing
- Fremanezumab
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Chronic Migraine, Episodic Migraine
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Conditions
- Chronic Migraine, Episodic Migraine, Migraine
- Trial name
- Atogepant PMSS (NCT06603558)
- Testing
- Atogepant
- Where
- 36 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- AbbVie
Episodic Migraine
Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain
Clinical study to determine the responder rate of the TheraNova Migraine Treatment System to that of a sham control treatment.
- Trial name
- NCT04166045
- Testing
- Verum Treatment Location
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Theranova, L.L.C.
Migraine Headache, Episodic
A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
This is a randomized, blinded study designed to assess the efficacy of a portable, non-invasive neuromodulation system for the treatment of episodic migraine headaches.
- Trial name
- NCT01899040
- Testing
- neuromodulation for episodic migraine headache
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 100 people
- Sponsor
- Scion NeuroStim